Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Open Label, Dose Escalation Study to Characterize the Safety, Tolerability, and Efficacy of VUM02 Injection in Subjects With Idiopathic Pulmonary Fibrosis

NCT06230822 is registered in ClinicalTrials.gov with Wuhan Optics Valley Vcanbiopharma Co., Ltd. as lead sponsor.

NCT NCT06230822
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06230822 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Open Label, Dose Escalation Study to Characterize the Safety, Tolerability, and Efficacy of VUM02 Injection in Subjects With Idiopathic Pulmonary Fibrosis
Lead sponsor
Wuhan Optics Valley Vcanbiopharma Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
March 5, 2024
Completion date
August 1, 2025
Enrollment
9 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic pulmonary fibrosis